268 related articles for article (PubMed ID: 19859560)
1. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.
Lell B; Agnandji S; von Glasenapp I; Haertle S; Oyakhiromen S; Issifou S; Vekemans J; Leach A; Lievens M; Dubois MC; Demoitie MA; Carter T; Villafana T; Ballou WR; Cohen J; Kremsner PG
PLoS One; 2009 Oct; 4(10):e7611. PubMed ID: 19859560
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
[TBL] [Abstract][Full Text] [Related]
4. Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).
Agnandji ST; Fendel R; Mestré M; Janssens M; Vekemans J; Held J; Gnansounou F; Haertle S; von Glasenapp I; Oyakhirome S; Mewono L; Moris P; Lievens M; Demoitie MA; Dubois PM; Villafana T; Jongert E; Olivier A; Cohen J; Esen M; Kremsner PG; Lell B; Mordmüller B
PLoS One; 2011 Apr; 6(4):e18559. PubMed ID: 21494604
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
7. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
Bojang K; Milligan P; Pinder M; Doherty T; Leach A; Ofori-Anyinam O; Lievens M; Kester K; Schaecher K; Ballou WR; Cohen J
Hum Vaccin; 2009 Apr; 5(4):242-7. PubMed ID: 19276646
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region.
Abdulla S; Salim N; Machera F; Kamata R; Juma O; Shomari M; Kubhoja S; Mohammed A; Mwangoka G; Aebi T; Mshinda H; Schellenberg D; Carter T; Villafana T; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
Malar J; 2013 Jan; 12():11. PubMed ID: 23297680
[TBL] [Abstract][Full Text] [Related]
9. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
10. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children.
Ansong D; Asante KP; Vekemans J; Owusu SK; Owusu R; Brobby NA; Dosoo D; Osei-Akoto A; Osei-Kwakye K; Asafo-Adjei E; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Janssens MH; Lievens MJ; Olivier AC; Jongert E; Dubois P; Savarese BM; Cohen J; Antwi S; Greenwood BM; Evans JA; Agbenyega T; Moris PJ; Owusu-Agyei S
PLoS One; 2011 Apr; 6(4):e18891. PubMed ID: 21556142
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.
Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ
Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M
Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182
[TBL] [Abstract][Full Text] [Related]
13. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.
Umeh R; Oguche S; Oguonu T; Pitmang S; Shu E; Onyia JT; Daniyam CA; Shwe D; Ahmad A; Jongert E; Catteau G; Lievens M; Ofori-Anyinam O; Leach A
Vaccine; 2014 Nov; 32(48):6556-62. PubMed ID: 25077418
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
[TBL] [Abstract][Full Text] [Related]
16. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
RTS,S Clinical Trials Partnership
PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
[TBL] [Abstract][Full Text] [Related]
19. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
Olotu A; Moris P; Mwacharo J; Vekemans J; Kimani D; Janssens M; Kai O; Jongert E; Lievens M; Leach A; Villafana T; Savarese B; Marsh K; Cohen J; Bejon P
PLoS One; 2011; 6(10):e25786. PubMed ID: 21998698
[TBL] [Abstract][Full Text] [Related]
20. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]